Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient.

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Abstract Text:

I Ohsawa,H Ohi,T Maruyama,H Hamada,Y Tomino,I Ohsawa,H Ohi,T Maruyama,H Hamada,Y Tomino,

A 57-year-old-woman, who was treated with regular maintenance hemodialysis (HD), newly contracted rheumatoid arthritis (RA). Oral predonisolone was effective for alleviating her arthralgia but the RA activity became steroid-dependent. For treatment of poorly controlled synovitis leukocytapheresis (LCAP) showed excellent efficacy in the treatment of her joint pain. No serious adverse effects were observed. Serological markers such as CRP, serum amyloid A, matrix metalloproteinase 3 and peripheral blood lymphocyte count fluctuated with her clinical symptoms. We recommend LCAP as candidate therapy for steroid-dependent patients with RA who are on maintenance HD.

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Publishing Authors By Initials

I Ohsawa,H Ohi,T Maruyama,H Hamada,Y Tomino,I Ohsawa,H Ohi,T Maruyama,H Hamada,Y Tomino,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical nephrology

VOLUME: 68

Page Numbers: 121-4

Journal Abbreviation: Clin. Nephrol.

ISSN: 0301-0430

DAY: 28

MONTH: Aug

YEAR: 2007

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 364441

Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient.

AFFILIATION: Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Nephrol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Leukocytapheresis LCAP for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient Related Publications

• Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration.
• Analysis of IgA nephropathy by serial renal biopsies in the ddY mouse: heterogeneous progression of glomerulonephritis.
• Antibiotics induce apoptosis of human peritoneal mesothelial cells.
• Biosynthesis of tropomyosin and troponin during development of the chicken skeletal muscle.
• Effect of educational hospitalization on chronic kidney disease (CKD) patients.
• Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-A(y)/Ta mice.
• Evaluation of parathyroid hyperplasia by ultrasonographic examination in patients with end-stage renal failure before and at initiation of dialysis.
• Improvement of peritoneal calcification after parathyroidectomy in a peritoneal dialysis patient.
• Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.
• Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
• Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient.
• Osteodystrophy in Indonesian haemodialysis patients.
• Peritoneal fibrosis intervention.
• Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis.
• Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy.
• Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models.
• Prediction of diagnosis of immunoglobulin a nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading.
• Preoperative autologous blood donation for cardiac surgery in children.
• Re-operation for Tetralogy of Fallot with Single Right Coronary Artery.
• Reduction of 2,4-disubstituted resorcinols.
• Relationship between Abdominal Fat Accumulation and Insulin Resistance in Hemodialysis Patients.
• STUDIES ON ORNITHINE-KETOACID TRANSAMINASE. I. PURIFICATION AND PROPERTIES.
• Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis.
• The role of podocytes in proteinuria.
• [A case of left atrial myxoma with acute myocardial infarction--emergency coronary artery bypass grafting and removal of left atrial myxoma]
• [A case of mitral valve replacement for Libman-Sacks endocarditis]
• [Chronic glomerulonephritis]
• [Overview of IgA nephropathy]
• [Pathogenesis of IgA nephropathy: current understanding of mucosa-bone marrow axis in IgA nephropathy]
• [Pulsatile extracorporal circulation. Experimental section: experimental study and designing of the apparatus]